Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.
Copy LinkSavePlay(1min)Comments(4)Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock news Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) said the FDA has granted Breakthrough Therapy designation for its antibody drug conjugate sacituzumab tirumotecan, also known as sac-TMT, for the treatment of a certain type of lung cancer.
Sac-TMT received the designation for the treatment of patients
Източник: seekingalpha.com
Тази статия е автоматично импортирана от външен източник. За оригиналното съдържание на пълната статия, моля посетете източника.